Hepatocellular Carcinoma and Vitamin K

Vitamins and Hormones

Volumn 78, Issue , 2008, Pages 435-442

  Mizuta, Toshihiko ^a   Ozaki, Iwata ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FARNOQUINONE; VITAMIN K GROUP;

HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; VITAMIN K; VITAMIN K 2;

EID: 40949163784     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(07)00018-0     Document Type: Review

References (26)

1. Bouzahazah B., Nishikawa Y., Simon D., and Carr B.I. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: Inhibitory actions of vitamin K. J. Cell. Physiol. 165 (1995) 459-467
2. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., and Karin M. IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107 (2001) 763-775
3. Carr B.I., Wang Z., and Siddhartha K. K vitamins, PTP antagonism, and cell growth arrest. J. Cell. Physiol. 193 (2002) 263-274
4. Chlebowski R.T., Dietrich M., Akman S., and Block J.B. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer. Treat. Rep. 69 (1985) 527-532
5. Fu M., Wang C., Rao M., Wu X., Bouras T., Zhang X., Li Z., Jiao X., Yang J., Li A., Perkins N.D., Thimmapaya B., et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J. Biol. Chem. 280 (2005) 29728-29742
6. Hitomi M., Yokoyama F., Kita Y., Nonomura T., Masaki T., Yoshiji H., Inoue H., Kinekawa F., Kurokohchi K., Uchida N., Watanabe S., and Kuriyama S. Antitumor effects of viatamin K1, K2, and K3 on hepatocellular carcinoma in vitro and in vivo. Int. J. Oncol. 26 (2005) 713-720
7. Kanamori T., Shimizu M., Okuno M., Matsushima-Nishiwaki R., Tsurumi H., Kojima S., and Moriwaki H. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci. 98 (2007) 431-437
8. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kB in cancer, from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
9. Kim H.J., Hawke N., and Baldwin A.S. NF-kB and IKK as therapeutic targets in cancer. Cell Death Differ. 13 (2006) 738-747
10. Li Z., Wang C., and Prendergast G. Cyclin D1 functions in cell migration. Cell Cycle 5 (2006) 2440-2442
11. Liu W., Nakamura H., Yamamoto T., Ikeda N., Saito M., Ohno M., Hara N., Imanishi H., Shinomura S., Yamamoto T., Sakai T., Nishiguchi S., et al. Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol. Res. 37 (2007) 360-365
12. Matsumoto K., Okano J., Nagahara T., and Murawaki Y. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int. J. Oncol. 29 (2006) 1501-1508
13. Mizuta T., Ozaki I., Eguchi Y., Yasutake T., Kawazoe S., Fujimoto K., and Yamamoto K. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: A pilot study. Cancer 15 (2006) 867-872
14. Nakamura M., Nagano H., Noda T., Wada H., Ota H., Damdinsuren B., Marubashi S., Miyamoto A., Takeda Y., Doki Y., Umeshita K., Dono K., et al. Vitamin K2 has growth inhibition effect against hepatocellular carcinoma cell lines but does not enhance anti-tumor effect of combination treatment of interferon-alpha and fluorouracil in vitro. Hepatol. Res. 35 (2006) 289-295
15. Ohsaki Y., Shirakawa H., Hiwatashi K., Furukawa Y., Mizutani T., and Komai M. Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci. Biotechnol. Biochem. 70 (2006) 926-932
16. Orimo H., Shiraki M., Tomita A., Morii H., Fujita T., and Ohata M. Effects of menatetrenone on the one and calcium metabolism in osteroporosis: A double-blind placebo control study. J. Bone Miner. Metab. 16 (1998) 106-112
17. Otsuka M., Kato N., Shao R.-X., Hoshida Y., Ijichi H., Koike Y., Taniguch H., Moriyama M., Shiratori Y., Kawabe T., and Omata M. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 40 (2004) 243-251
18. Ozaki I., Zhang H., Mizuta T., Ide Y., Eguchi Y., Yasutake T., Sakamaki T., Pestell R.G., and Yamamoto K. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibiton of nuclear factor kB activation. Clin. Cancer Res. 13 (2007) 2236-2245
19. Sakai I., Hashimoto S., Yoda M., Hida T., Ohsawa S., Nakajo S., and Nakaya K. Novel role of vitamin K2: A potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem. Biophys. Res. Commun. 205 (1994) 1305-1310
20. Saxena S.P., Fan T., Li M., Israels E.D., and Isralels L.G. A novel role for vitamin K1 in a tyrosine phosophorylation cascade during chick embryogenesis. J. Clin. Invest. 99 (1997) 602-607
21. Tabb M.M., Sun A., Zhou C., Grun F., Errandi J., Romero K., Pham H., Inoue S., Mallick S., Lin M., Forman B.M., and Blumberg B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 278 (2003) 43919-43927
22. Takeuchi Y., Suzawa M., Fukumoto S., and Fujita T. Vitamin K2 inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell culture. Bone 27 (2000) 769-776
23. Wang Z., Wang M., Finn F., and Carr B.I. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 22 (1995) 876-882
24. Yaguchi M., Miyazawa K., Otawa M., Katagiri T., Nishimaki J., Uchida Y., Iwase O., Gotoh A., Kawanishi Y., and Toyama K. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: Flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 12 (1998) 1392-1397
25. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., Namisaki T., Kitade M., Yamazaki M., Masaki T., and Fukui H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol. 42 (2005) 687-693
26. Zhou C., Tabb M.M., Nelson E.L., Grun F., Verma S., Sadatrafiei A., Lin M., Mallick S., Forman B.M., Thummel K.E., and Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kB signaling pathways links xenobiotic maetabolism and inflammation. J. Clin. Invest. 116 (2006) 2280-2289